NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis $1.15 +0.01 (+0.88%) As of 02:25 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Onconetix Stock (NASDAQ:ONCO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Onconetix alerts:Sign Up Key Stats Today's Range$1.12▼$1.1950-Day Range$1.10▼$32.2052-Week Range$0.91▼$382.50Volume406,144 shsAverage Volume1.36 million shsMarket Capitalization$1.31 millionP/E Ratio0.10Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. Read More Onconetix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreONCO MarketRank™: Onconetix scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingOnconetix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageOnconetix has only been the subject of 1 research reports in the past 90 days.Read more about Onconetix's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconetix is 0.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconetix is 0.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.10.Price to Book Value per Share RatioOnconetix has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Onconetix's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.96% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently decreased by 89.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnconetix does not currently pay a dividend.Dividend GrowthOnconetix does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.43 News SentimentOnconetix has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Onconetix this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ONCO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership3.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $8,404.00 in company stock, which represents 0.6582% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Onconetix insiders have bought 5.82% more of their company's stock than they have sold. Specifically, they have bought $152,867.00 in company stock and sold $144,463.00 in company stock.Percentage Held by Insiders0.27% of the stock of Onconetix is held by insiders.Percentage Held by Institutions23.89% of the stock of Onconetix is held by institutions.Read more about Onconetix's insider trading history. Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCO Stock News HeadlinesOnconetix (NASDAQ:ONCO) Downgraded to "Sell" Rating by Wall Street ZenMay 23, 2026 | americanbankingnews.comOnconetix, Inc. Announces 1-for-10 Reverse Stock SplitMay 19, 2026 | globenewswire.comSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just revealed 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - are competing for a role in what Wall Street is calling 'Project Apex,' a potential $1.75 trillion listing Bloomberg has dubbed the biggest of all time. Dr. Mark Skousen, Macroeconomic Strategist at The Oxford Club, says a pre-IPO 'backdoor' entry still exists - and nearly 15,000 investors have already accessed his free recommendation. June is the reported target date, and the window is narrowing.June 2 at 1:00 AM | The Oxford Club (Ad)Realbotix Provides Update on Nasdaq ListingMay 19, 2026 | businesswire.comOnconetix Inc. Reports New Clinical Data Supporting Proclarix® in Reducing Overdiagnosis and Launches PRIME Study with LabcorpMay 13, 2026 | quiverquant.comQOnconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation StudyMay 13, 2026 | globenewswire.comOnconetix Shareholders Approve Flexible Reverse Stock Split AuthorizationMay 8, 2026 | theglobeandmail.comOnconetix Reshapes Board Leadership With New Chairman, DirectorApril 24, 2026 | tipranks.comSee More Headlines ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed this year? Onconetix's stock was trading at $78.00 on January 1st, 2026. Since then, ONCO stock has decreased by 98.6% and is now trading at $1.12. How were Onconetix's earnings last quarter? Onconetix, Inc. (NASDAQ:ONCO) released its quarterly earnings results on Wednesday, May, 13th. The company reported ($67.10) earnings per share (EPS) for the quarter. The firm earned $0.02 million during the quarter. Onconetix had a negative net margin of 1,316.28% and a negative trailing twelve-month return on equity of 101.08%. When did Onconetix's stock split? Onconetix shares reverse split on the morning of Friday, May 22nd 2026.The 1-10 reverse split was announced on Tuesday, May 19th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 21st 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Onconetix IPO? Onconetix (ONCO) raised $20 million in an initial public offering on Thursday, February 17th 2022. The company issued 2,222,222 shares at $8.00-$10.00 per share. How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Onconetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include Qualcomm (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI). Company Calendar Last Earnings5/13/2026Today6/02/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ONCO's financial health is in the Red zone, according to TradeSmith. ONCO has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)$11.40 Trailing P/E Ratio0.10 Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.03 million Net Margins-1,316.28% Pretax Margin-1,316.28% Return on Equity-101.08% Return on Assets-47.34% Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick Ratio1.37 Sales & Book Value Annual Sales$735.20 thousand Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book Value$505.29 per share Price / Book0.00Miscellaneous Outstanding Shares1,140,000Free Float1,137,000Market Cap$1.28 million OptionableN/A Beta3.01 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ONCO) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersThe Rare Earth Shift Few Saw ComingRare earth elements sit inside modern defense systems, high-performance magnets, and advanced electronics - ye...i2i Marketing Group, LLC | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredOver 90 Years Later, Trump May Finally Reverse 1933's Gold HeistTucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...American Hartford Gold | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
